Human papillomavirus-related oropharyngeal carcinoma

Jpn J Clin Oncol. 2022 Jul 8;52(7):700-706. doi: 10.1093/jjco/hyac049.


It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with clinical presentations different from nonrelated head and neck carcinoma. Twenty years after and with the revision of the tumor-node-metastasis classification in 2017, various clinical trials focused on human papillomavirus-related oropharyngeal carcinoma to improve the prognosis and quality of life of patients with this disease. However, the incidence of human papillomavirus-related cancers is increasing, which is expected to be particularly prominent in Japan, where human papillomavirus vaccination is not widely available. In this review, we describe the current status of clinical trials (mainly focused on initial surgery and radiation dose reduction) for, primary and secondary prevention of, and the present status of human papillomavirus-related oropharyngeal carcinoma in Japan.

Keywords: HNSCC; Japan; human papillomavirus; oropharyngeal carcinoma; p16.

Publication types

  • Review

MeSH terms

  • Alphapapillomavirus*
  • Carcinoma, Squamous Cell* / pathology
  • Head and Neck Neoplasms*
  • Humans
  • Oropharyngeal Neoplasms* / pathology
  • Oropharyngeal Neoplasms* / therapy
  • Papillomaviridae
  • Papillomavirus Infections* / complications
  • Papillomavirus Vaccines* / therapeutic use
  • Quality of Life


  • Papillomavirus Vaccines